Core Insights - AMD and the U.S. Department of Energy (DOE) announced two next-generation supercomputers, Lux AI and Discovery, aimed at enhancing U.S. leadership in artificial intelligence (AI) and high-performance computing (HPC) [2][3] - The combined investment for these systems is projected to be $1 billion, sourced from both private and public funding, to establish a secure AI infrastructure in the U.S. [3][7] Group 1: Supercomputer Details - The Lux AI supercomputer, co-developed with ORNL, Oracle Cloud Infrastructure, and HPE, will be the first dedicated U.S. AI factory for science, set to be deployed in early 2026 [4][9] - Discovery will feature next-gen AMD EPYC CPUs and MI430X GPUs, designed specifically for sovereign AI and scientific computing, and is expected to be operational by 2029 [5][16] - Both supercomputers will support the U.S. AI Action Plan by accelerating AI-enabled science and enhancing national competitiveness [7][10] Group 2: Strategic Partnerships - The collaboration between AMD, DOE, ORNL, HPE, and Oracle emphasizes the importance of public-private partnerships in advancing scientific research and innovation [4][8] - U.S. Secretary of Energy Chris Wright highlighted the need for creative partnerships to maintain leadership in AI and science [6] - The partnership aims to leverage advanced computing technologies to address challenges in energy, medicine, and national security [3][4] Group 3: Expected Outcomes - Lux is designed to enhance the U.S. capacity for scientific AI, facilitating breakthroughs in various fields including energy innovation and national security [10][11] - Discovery aims to deliver higher performance and energy efficiency, driving advancements in critical areas such as advanced materials and manufacturing [14][17] - The integration of AI and HPC through these supercomputers is expected to significantly accelerate the pace of scientific innovation in the U.S. [12][13]

Core Insights - Absci collaborates with Oracle Cloud Infrastructure (OCI) and AMD to enhance its generative AI-driven drug discovery platform, aiming to accelerate biologics design cycles and reduce costs [1][2][3] Company Overview - Absci is a clinical-stage biotech company focused on advancing novel therapeutics using generative AI, with a mission to create better biologics for patients more quickly [5] - The company utilizes an Integrated Drug Creation™ platform that combines advanced AI models with a synthetic biology data engine, facilitating rapid design and validation of therapeutics [5] Technology and Infrastructure - Absci has selected OCI as the technical foundation for developing AI models and scaling AI workflows, enabling large-scale molecular-dynamics simulations and end-to-end antibody design [2][3] - The collaboration leverages OCI's bare metal instances powered by 5th Generation AMD EPYC™ processors and ultrafast RDMA networking, providing low-latency networking and high throughput for model training and simulations [3][4] - The integration of AMD's next-generation Instinct™ MI355X GPUs further enhances the performance and scalability of Absci's AI Drug Creation Platform [2][4] Industry Impact - The partnership between Absci, OCI, and AMD exemplifies how AI can transform drug discovery processes, accelerating the development of novel therapeutics [4] - The collaboration aims to push the boundaries of biologics design by combining cutting-edge AI models with high-performance infrastructure [3][4]